医疗反腐持续进行,本就业绩承压的 白云山 又出现内控失守的情况。2月14日,四川省药械招标采购服务中心公布了7家药企的致歉声明,其中就包括白云山子公司广药四川医药有限公司。广药四川致歉声明显示,该公司销售人员在销售过程中,向相关人员给予不正当利益,已对涉事员工做开除处理。2023年年报显示,白云山在西南地区报告期内主营业务收入约50.05亿元,占比约6.6%。在公司6个业务地区中(不包括出口),...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.